Study, year of publication Study treatment Comparators CE ratio CE ratio IFX Archer et al., 2016 [40 ] IFX Surgery Dominated Dominated IFX ADA Dominated Dominated Chaudhary and Fan, 2013 [41 ] IFX Cyclosporine €24,277/QALY $34,241/QALY IFX Surgery €14,639/QALY $20,647/QALY Hyde et al., 2009 [42 ] Strategy A (IFX responders who achieved and maintained remission and mild health states) Std care £33,866/QALY $78,180/QALY Strategy B (IFX responders who achieved and maintained remission) Std care £25,044/QALY $57,814/QALY Punekar and Hawkins, 2010 [43 ] IFX Cyclosporine £19,545/QALY $50,571/QALY IFX Std care £18,388/QALY $47,578/QALY Stawowczyk et al., 2016 [44 ] IFX + std care Std care $106,743/QALY $135,934/QALY Thorlund et al. , 2014 [45 ] IFX Std care $65,982/QALY (CAD 2013) $68,093/QALY IFX ADA Dominant Dominant Toor et al. , 2015 [46 ] IFX Std care $1,975/Remission (CAD 2015) $2,038/Remission IFX Std care $1,311/Response (CAD 2015) $1,352/Response IFX GOL (100 mg) $14,659/Remission (CAD 2015) $15,128/Remission IFX GOL $4,753/Response (CAD 2015) $4,905/Response Tsai et al., 2008 [47 ] IFX MTN (responder strategy) Std care £27,424/QALY $70,958/QALY IFX MTN (remission strategy) Std care £19,696/QALY $50,962/QALY Ung et al. , 2014 [48 ] IFX Std care $79,000/QALY (USD 2013) $85,596/QALY Williams et al., 2016 [49 ] IFX Cyclosporin Dominated Dominated Yokomizo et al., 2016 [50 ] IFX (5 mg/kg) IFX (10 mg/kg) $1,243,310/MH $1,366,933/MH IFX (5 mg/kg) ADA Dominated Dominated IFX (5 mg/kg) VED Dominated Dominated ADA Archer et al., 2016 [40 ] ADA Surgery Dominated Dominated ADA Std care £50,278/QALY $83,804/QALY Thorlund et al. , 2014 [45 ] ADA Std care $68,722/QALY (CAD 2013) $70,921/QALY Toor et al. , 2015 [46 ] ADA Std care $7,430/Remission (CAD 2015) $7,667/Remission ADA Std care $2,361/Response (CAD 2015) $2,436/Response ADA GOL (100 mg) Dominated Dominated ADA GOL (100 mg) Dominated Dominated IFX and ADA Xie et al. , 2009 [51 ] IFX (5 mg/kg) then ADA (5 mg/kg) Std care $358,088/QALY (CAD 2008) $402,490/QALY IFX (5 mg/kg) then ADA (10 mg/kg) Std care $575,540/QALY (CAD 2008) $646,907/QALY Other biologics (GOL, NAT, VED) Archer et al., 2016 [40 ] GOL Surgery Dominated Dominated Essat et al., 2016 [52 ] VED Std care £33,297/QALY $54,283/QALY VED Surgery Dominant Dominant VED (Anti-TNF naïve pt) IFX (Anti-TNF naïve pt) Dominant Dominant VED (Anti-TNF naïve pt) GOL (Anti-TNF naïve pt) Dominant Dominant VED (Anti-TNF naïve pt) ADA (Anti-TNF naïve pt) £6,634/QALY $10,815/QALY VED (Anti-TNF naïve pt) Std care (Anti-TNF naïve pt) £4,862/QALY $7,926/QALY VED (Anti-TNF naïve pt) Surgery (Anti-TNF naïve pt) Dominant Dominant VED (Anti-TNF failure) Std care (Anti-TNF failure) £64,999/QALY $105,966/QALY VED (Anti-TNF failure) Surgery (Anti-TNF failure) Dominant Dominant Thorlund et al. , 2014 [45 ] GOL (50 mg) Std care $41,591/QALY (CAD 2013) $42,921/QALY GOL (100 mg) Std care $42,271/QALY (CAD 2013) $43,623/QALY GOL (50 mg) IFX Dominant Dominant GOL (100 mg) IFX Dominant Dominant GOL (50 mg) ADA Dominant Dominant GOL (100 mg) ADA Dominant Dominant Toor et al. , 2015 [46 ] GOL (100 mg) Std care $935/Remission (CAD 2015) $964/Remission GOL (100 mg) Std care $701/Response (CAD 2015) $723/Response GOL (50 mg) Std care $1,048/Remission (CAD 2015) $1,081/Remission GOL (50 mg) GOL (100 mg) $207/Remission (CAD 2015) $213/Remission GOL (50 mg) Std care $770/Response (CAD 2015) $794/Response GOL (50 mg) GOL (100 mg) $224/Response (CAD 2015) $231/Response 5-ASA Brereton et al., 2010 [53 ] 5-ASA (Mezavant XL, MMX) 5-ASA (Asacol) £749/QALY $2,058/QALY Buckland and Bodger, 2008 [54 ] 5-ASA (High dose, Asacol) 5-ASA (Std dose, Asacol) Dominant Dominant Connolly et al., 2009 [55 ] 5-ASA (Oral + topical) 5-ASA (Oral) Dominant Dominant Connolly et al., 2009 [56 ] 5-ASA (2 g once daily) 5-ASA (1 g twice daily) Dominant Dominant Connolly et al., 2012 [57 ] 5-ASA (Oral + topical) 5-ASA (Oral) Dominant Dominant 5-ASA (2 g once daily) 5-ASA (1 g twice daily) Dominant Dominant Connolly et al., 2014 [58 ] 5-ASA (2 g once daily) 5-ASA (1 g twice daily + enema) Dominant Dominant Mackowiak, 2006 [59 ] Oral balsalazide capsules Oral 5-ASA specific formulation Dominant Dominant Nishikawa et al., 2013 [60 ] 5-ASA (once daily) 5-ASA (twice daily) $86,200/LYG $55,649/LYG Prenzler et al., 2011 [61 ] 5-ASA (Mezavant XL, MMX) 5-ASA (Asacol) Dominant Dominant Saini et al., 2012 [62 ] SYMPT (5-ASA treatment for symptomatic disease flares only) INFLAM (5-ASA therapy for only patients with a stool sample positive for an inflammatory marker) $575,894/QALY $715,331/QALY SYMPT (5-ASA treatment for symptomatic disease flares only) CONT (continuous 5-ASA maintenance) Dominant Dominant Yen et al., 2008 [63 ] MTN 5-ASA (2.4 g/day escalated and maintained at 4.8 g/day after the first flare) No MTN 5-ASA (5-ASA 4.8 g/day given for flares) $224,000/QALY $353,545/QALY Immunosuppressants (AZA, 6MP, cyclosporine) Priest et al., 2006 [39 ] AZA MTX Dominant Dominant AZA No immunosuppressant therapy Dominant Dominant Punekar and Hawkins, 2010 [43 ] Cyclosporine Standard care Dominant Dominant Cyclosporine Surgery £9,032/QALY $23,370/QALY Surgery Archer et al., 2015 [40 ] Surgery (colectomy) Std care Dominant Dominant Park et al., 2012 [64 ] Surgery (early colectomy + IPAA) Std care $1,476,783/QALY $1,834,347/QALY Swenson et al., 2005 [65 ] Two-Stage IPAA Three-Stage IPAA Dominant Dominant GMA Panes et al., 2007 [66 ] GMA Std care €23,898/Remission $45,864/Remission
